Cure My Disease

Don't miss your cure!

 Log in / Sign up

Timing is everything: new study tests if stem cell infusion time prevents transplant complications

NCT ID NCT06294678

Ongoing Knowledge-focused Sponsor: Anhui Provincial Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether the time when stem cells are given to blood cancer patients after a donor transplant affects their risk of developing acute graft-versus-host disease (aGVHD), a serious complication where donor cells attack the patient's body. About 198 patients aged 12-60 will be randomly assigned to receive their stem cell infusion at different times. The main goal is to see if timing can lower the chance of moderate to severe aGVHD in the first 100 days after transplant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute graft versus host disease hematopoietic and lymphoid cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE GRAFT VERSUS HOST DISEASE

Contacts and locations

Locations

  • Peking University First Hospital

    Beijing, Beijing Municipality, 100000, China

  • Rui Jin Hospital Affiliated to Shanghai Jiao Tong University

    Shanghai, Shanghai Municipality, 200000, China

  • The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)

    Hefei, Anhui, 230036, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, 450000, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310000, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.